CorestemChemon's biopharmaceutical division aims to develop new drugs based on stem cell therapy technology. They are currently conducting clinical trials targeting neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), cerebellar ataxia, and multiple sclerosis. Additionally, we are conducting research and development focused on autoimmune diseases, specifically systemic lupus erythematosus (SLE) and fibrosis.

The Nonclinical CRO business unit is conducting both toxicity and efficacy evaluations which are essential initial steps towards obtaining regulatory approval for a wide range of pharmaceuticals, biopharmaceuticals, cosmetics, and medical devices. As animal-based toxicity and efficacy assessments continue to grow in importance, such evaluations are a critical aspect of drug development and represent a rapidly expanding market segment.